Description

Book Synopsis
Japan has succeeded in many industries through its renowned production system. Competitive advantage, however, in the new economy is shifting from production to demand-based capabilities. One such new industry is pharmaceuticals, where Japan has been a resounding failure, both from public policy and corporate strategy perspectives. This book provides a detailed examination of how Japan has socially constructed its pharmaceutical industry, the economic and political bases of this construction and the consequences for corporate innovation and performance.

Perhaps the starkest indication of this failure of Japanese public policy is the emergence of a new drug lag in that nation. Almost 90 percent of recent important new drugs are unavailable in Japan, despite their widespread diffusion throughout the rest of the world. Analysis of this drug lag confirms that it is not due to government discrimination against Western firms, but rather is only one of many consequences of failed Japanese industrial policies.

The author presents an analysis of the nature, causes and consequences of the new drug lag in Japan. He contrasts the problem with the one experienced in the US and looks at the powerful role played by domestic politics in shaping the pharmaceutical industry. The last chapters look at the various remedies available. Academics, experts in government and industry, researchers and students of industrial policy, economics, public health and trade policy will find the examination of this important industry both informative and enlightening.



Table of Contents
Contents: Introduction 1. Nature of the New Drug Lag 2. Industrial Policy and Domestic Ecosystems 3. The Domestic Japanese Ecosystem for Pharmaceuticals 4. Pathologies of the Japanese Domestic Ecosystem 5. Evidence: Declining Prices and Life Cycle Sales in Japan 6. Evidence: Declining Registrations in Japan 7. Evidence: Declining Launches in Japan 8. Evidence: Inflated Domestic Market Share in Japan 9. Challenges to the Dual State in Japan 10. Trade Law and Remedies for Market Exclusion References Index

The Japanese Pharmaceutical Industry: The New

    Product form

    £95.00

    Includes FREE delivery

    Order before 4pm today for delivery by Tue 30 Jun 2026.

    A Hardback by L. G. Thomas, III

      Trusted by thousands of customers. See 2,385+ Customer Reviews

      View other formats and editions of The Japanese Pharmaceutical Industry: The New by L. G. Thomas, III

      Publisher: Edward Elgar Publishing Ltd
      Publication Date: 28/08/2001
      ISBN13: 9781840645804, 978-1840645804
      ISBN10: 1840645806

      Description

      Book Synopsis
      Japan has succeeded in many industries through its renowned production system. Competitive advantage, however, in the new economy is shifting from production to demand-based capabilities. One such new industry is pharmaceuticals, where Japan has been a resounding failure, both from public policy and corporate strategy perspectives. This book provides a detailed examination of how Japan has socially constructed its pharmaceutical industry, the economic and political bases of this construction and the consequences for corporate innovation and performance.

      Perhaps the starkest indication of this failure of Japanese public policy is the emergence of a new drug lag in that nation. Almost 90 percent of recent important new drugs are unavailable in Japan, despite their widespread diffusion throughout the rest of the world. Analysis of this drug lag confirms that it is not due to government discrimination against Western firms, but rather is only one of many consequences of failed Japanese industrial policies.

      The author presents an analysis of the nature, causes and consequences of the new drug lag in Japan. He contrasts the problem with the one experienced in the US and looks at the powerful role played by domestic politics in shaping the pharmaceutical industry. The last chapters look at the various remedies available. Academics, experts in government and industry, researchers and students of industrial policy, economics, public health and trade policy will find the examination of this important industry both informative and enlightening.



      Table of Contents
      Contents: Introduction 1. Nature of the New Drug Lag 2. Industrial Policy and Domestic Ecosystems 3. The Domestic Japanese Ecosystem for Pharmaceuticals 4. Pathologies of the Japanese Domestic Ecosystem 5. Evidence: Declining Prices and Life Cycle Sales in Japan 6. Evidence: Declining Registrations in Japan 7. Evidence: Declining Launches in Japan 8. Evidence: Inflated Domestic Market Share in Japan 9. Challenges to the Dual State in Japan 10. Trade Law and Remedies for Market Exclusion References Index

      Recently viewed products

      © 2026 Book Curl

        • American Express
        • Apple Pay
        • Diners Club
        • Discover
        • Google Pay
        • Maestro
        • Mastercard
        • PayPal
        • Shop Pay
        • Union Pay
        • Visa

        Login

        Forgot your password?

        Don't have an account yet?
        Create account